Clinical Trial Update: Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

This clinical trial update indicates the long-term safety study of vildagliptin in type 2 diabetes has been completed (Phase 3), sponsored by Novartis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Vildagliptin (vildagliptin)

Snippet

Sponsor: Novartis | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED